Background: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized. Method: Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed. Results: No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1—anaphylaxis to injectable drug or vaccine con...
The first approved COVID-19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA-1273 and AstraZe...
Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) imm...
Following the emergency use authorization of the mRNA-1273 vaccine on the 18th of December 2020, two...
Background: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its manage...
Anaphylaxis, which is rare, has been reported after COVID 19 vaccination, but its management is not ...
BACKGROUND Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its mana...
Purpose of review Whereas the COVID-19 pandemic has changed our lives worldwide, we hope that vaccin...
Adverse allergic reactions due to the administration of the vaccines developed for the protection of...
BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented...
For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global rese...
Klimek L, Bergmann K-C, Brehler R, et al. Practical handling of allergic reactions to COVID-19 vacci...
Although allergic responses to the mRNA COVID-19 vaccines are rare, recent reports have suggested th...
The newly developed mRNA-based COVID-19 vaccines can provoke anaphylaxis, possibly induced by polyet...
The first approved COVID-19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA-1273 and AstraZe...
Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) imm...
The first approved COVID-19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA-1273 and AstraZe...
Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) imm...
Following the emergency use authorization of the mRNA-1273 vaccine on the 18th of December 2020, two...
Background: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its manage...
Anaphylaxis, which is rare, has been reported after COVID 19 vaccination, but its management is not ...
BACKGROUND Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its mana...
Purpose of review Whereas the COVID-19 pandemic has changed our lives worldwide, we hope that vaccin...
Adverse allergic reactions due to the administration of the vaccines developed for the protection of...
BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented...
For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global rese...
Klimek L, Bergmann K-C, Brehler R, et al. Practical handling of allergic reactions to COVID-19 vacci...
Although allergic responses to the mRNA COVID-19 vaccines are rare, recent reports have suggested th...
The newly developed mRNA-based COVID-19 vaccines can provoke anaphylaxis, possibly induced by polyet...
The first approved COVID-19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA-1273 and AstraZe...
Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) imm...
The first approved COVID-19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA-1273 and AstraZe...
Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) imm...
Following the emergency use authorization of the mRNA-1273 vaccine on the 18th of December 2020, two...